Abstract 1733P
Background
Metronomic dosing of Gemcitabine, Doxorubicin and Docetaxel causes less severe side effects than standard chemotherapy for advanced sarcoma.
Methods
Primary objective: To assess progression-free survival (PFS); Secondary objectives: (1) To evaluate best overall response during treatment period confirmed in a 6-week follow-up, (2) PFS rate at 6 and 9 months, (3) Overall survival (OS) rate at 6, 12 months, and (4) Incidence of treatment-related adverse events (TRAEs). Inclusion criteria: Previously treated male and female subjects, ≥ 18 years of age, pathologically confirmed diagnosis of locally advanced, unresectable, or metastatic sarcoma, measurable disease by RECIST v1.1, and acceptable hematologic and organ functions. Exclusion Criteria: History of autoimmune disorder. Treatment schedule: Metronomic doses of gemcitabine (600 mg/m2 max:1000 mg), doxorubicin (18 mg/m2; max: 32 mg), docetaxel (25 mg/m2; max:42 mg) on Day 1 and Day 8, and nivolumab (240 mg) on Day 1 only. Repeat treatment cycles may be given every three weeks if the toxicity grade is ≤ 1.
Results
Efficacy (n=74). This population completed at least two treatment cycle and had a follow-up CT or MRI scan at week 6. Best Overall Response = 1 CR, 13 PR, 50 SD, 10 PD. The disease control rate (CR+PR+SD) was 86%. Median PFS was 8.2 (95% CI: 6.4-10.0) months; 6-month PFS rate of 60% and 9-month PFS rate of 46%. Median OS was 17.6 (95% CI: 13.7-21.5) months, with 6-month OS of 84% and 9-month OS of 68%. Safety (n=76): Grade 3/4 TRAEs include thrombocytopenia (n=26), white blood cell count decreased (n=17), neutropenia (n=16), fatigue (n=15), anemia (n=13), nausea (n=9), anorexia (n=5), diarrhea (n=2), emesis (n=1), febrile neutropenia (n=1), sepsis (n=1), rectal bleeding (n=1), transaminitis (n=1), dizziness (n=1), shortness of breath (n=1). There were no unexpected adverse events reported.
Conclusions
Taken together, the data suggests that nivolumab plus metronomic doses of gemcitabine, doxorubicin and docetaxel (1) may have synergistic activity, and (2) by indirect comparison, may be as effective as standard first line therapy for advanced sarcoma with manageable toxicity.
Clinical trial identification
NCT04535713.
Editorial acknowledgement
Legal entity responsible for the study
Sarcoma Oncology Research Center, LLC.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Presenter: Marco Russano
Session: Poster session 06
1353P - Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancer
Presenter: Konstantinos Ferentinos
Session: Poster session 06
1354P - Retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLC
Presenter: Deevyashali Parekh
Session: Poster session 06
1356P - Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
Presenter: Elba Marin
Session: Poster session 06
1357P - Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
Presenter: Hiroshige Yoshioka
Session: Poster session 06
1358P - Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial
Presenter: Trevor Feinstein
Session: Poster session 06
1359P - Lack of Abscopal effect and radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapy
Presenter: Alexander Meisel
Session: Poster session 06
1361P - The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS
Presenter: Andreas Koulouris
Session: Poster session 06